Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic Nasopharyngeal Carcinoma After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

NCT07101744 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07101744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07101744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic Nasopharyngeal Carcinoma After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
October 17, 2025
Completion date
July 16, 2030
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

first-line treatment failure nasopharyngeal carcinoma, nasopharyngeal carcinoma (npc)